Amneal Pharmaceuticals (STU:2DT) Treasury Stock: €0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2DT Amneal Pharmaceuticals Inc STU:2DT
63 GF Score
Price €15.90
GF Value €7.08
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals Treasury Stock?

Amneal Pharmaceuticals STU:2DT 63 Treasury Stock is €0 Mil as of Jun. 2026. GuruFocus rates STU:2DT with a GF Score™ of 63/100 and a GF Value™ of €7.08 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Amneal Pharmaceuticals's treasury stock for the quarter that ended in Jun. 2026 was €0 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Amneal Pharmaceuticals Treasury Stock Historical Data

* Premium members only.

The historical data trend for Amneal Pharmaceuticals's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals Treasury Stock Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Amneal Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:2DT
63GF Score
Amneal Pharmaceuticals Inc STU:2DT
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amneal Pharmaceuticals Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of €0 Mil mean?
Amneal Pharmaceuticals (STU:2DT) has a Treasury Stock of €0 Mil as of Jun. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Amneal Pharmaceuticals and its competitors.
Is Amneal Pharmaceuticals' Treasury Stock too high?
Amneal Pharmaceuticals' current Treasury Stock is €0 Mil. Overall, Amneal Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Treasury Stock compare to HIMS and KNSA?
Amneal Pharmaceuticals' Treasury Stock of €0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Drug Manufacturers company?
A good Treasury Stock depends on the Drug Manufacturers industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Amneal Pharmaceuticals and its competitors. Amneal Pharmaceuticals's current Treasury Stock is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (STU:2DT) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.08, compared to a current price of €15.90 — trading 124.6% above its estimated fair value. The current Treasury Stock is €0 Mil. Amneal Pharmaceuticals' overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Amneal Pharmaceuticals (STU:2DT), the current Treasury Stock is €0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amneal Pharmaceuticals (STU:2DT) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of €15.90 is trading 124.6% above its estimated GF Value™ of €7.08. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:2DT:

  • Treasury Stock: €0 Mil
  • GF Value™: €7.08 vs. price of €15.90 (124.6% above fair value)
  • GF Score™: 63/100 with 7 warning signs

No single metric tells the full story. See the STU:2DT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Other Exchanges AMRX:USA
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
63GF Score

Get the complete analysis for STU:2DT

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.90
Price
€7.08
GF Value